SCHEMBL16267698

SCHEMBL16267698

CCc1ccc(Cl)c(CC(=O)O)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 1/20 0.47
PTGDR2 Q9Y5Y4 1/20 0.42
RAB9A P51151 1/20 0.42
GFER P55789 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
ALDH1A1 P00352 4/20 0.41
KDM4E B2RXH2 2/20 0.41
CXCL8 P10145 1/20 0.41
CYP2C9 P11712 1/20 0.41
HPGD P15428 1/20 0.41
HSD17B10 Q99714 1/20 0.41
FABP4 P15090 1/20 0.40
FABP5 Q01469 1/20 0.40
AKR1B1 P15121 1/20 0.40
FFAR1 O14842 1/20 0.40
FFAR4 Q5NUL3 1/20 0.40
CYP4F2 P78329 1/20 0.40
CYP4A11 Q02928 1/20 0.40
SLC22A12 Q96S37 1/20 0.39
PTGS2 P35354 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19289791 0.86 AKT1 (0.42) CA2SMN1; SMN2ALDH1A1KDM4ECYP4F2
SCHEMBL6069968 0.86 CA2 (0.51) CA2ALDH1A1HPGDHSD17B10AKR1B1
SCHEMBL510145 0.83 ALDH1A1 (0.45) CA2ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL31254084 0.83 ALDH1A1 (0.45) CA2ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL3790563 0.82 TRPA1 (0.43) RAB9ASMN1; SMN2ALDH1A1KDM4ECYP4F2
SCHEMBL31162368 0.82 CA2 (0.47) CA2RAB9AGFERSMN1; SMN2KDM4E
SCHEMBL14420099 0.81 TSHR (0.44) RAB9AGFERSMN1; SMN2ALDH1A1CYP4F2
SCHEMBL17424894 0.80 SMN1; SMN2 (0.45) CA2SMN1; SMN2ALDH1A1KDM4EHPGD
SCHEMBL9411180 0.79 PKM (0.47) PTGDR2ALDH1A1KDM4ECXCL8CYP2C9
SCHEMBL19289794 0.79 TRPA1 (0.38) RAB9ASMN1; SMN2ALDH1A1KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3004061-B1 3,4-DIHYDROISOQUINOLIN-2(1H)-YL COMPOUNDS LILLY CO ELI (US) 2017-08-30 EP disclosed
US-8962654-B2 3,4-dihydroisoquinolin-2(1H)-yl compounds ELI LILLY AND COMPANY (US) 2015-02-24 US disclosed
US-8962654-B2 3,4-dihydroisoquinolin-2(1H)-yl compounds ELI LILLY AND COMPANY (US) 2015-02-24 US disclosed
US-8962654-B2 3,4-dihydroisoquinolin-2(1H)-yl compounds ELI LILLY AND COMPANY (US) 2015-02-24 US disclosed
US-20140357664-A1 3,4-DIHYDROISOQUINOLIN-2(1H)-YL COMPOUNDS ELI LILLY AND COMPANY (US) 2014-12-04 US disclosed
US-20140357664-A1 3,4-DIHYDROISOQUINOLIN-2(1H)-YL COMPOUNDS ELI LILLY AND COMPANY (US) 2014-12-04 US disclosed
US-20140357664-A1 3,4-DIHYDROISOQUINOLIN-2(1H)-YL COMPOUNDS ELI LILLY AND COMPANY (US) 2014-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140357664-A1 3,4-DIHYDROISOQUINOLIN-2(1H)-YL COMPOUNDS PARK7, SNCA, COMT CA2 4261/4885PTGDR2 587/4885RAB9A 184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.